ARPA‑H awarded up to $31.7 million to a PREDICTS consortium led by Ginkgo Bioworks and Deep Origin to develop non‑animal in silico and ex vivo systems for drug safety and dosing prediction. The project will integrate perturbation response profiling, DRUG‑seq transcriptomics, and cell painting to train computational models that aim to replace some preclinical animal studies. Consortium partners include ImmVue Therapeutics, Mido, Netrias, Sanford Burnham Prebys and others; Ginkgo will provide structured datasets from multi‑cell perturbations and Deep Origin will contribute digital models for drug dynamics and molecular property prediction. ARPA‑H framed the effort as a step toward human‑relevant toxicology and improved dose selection for clinical trials. If successful, the PREDICTS program could change preclinical testing paradigms and reduce reliance on animal studies while improving early safety prediction.